We recently published 10 Big Names Bleed Double Digits. Hims & Hers Health, Inc. (NYSE:HIMS) is one of the worst-performing ...

Hims & Hers is a top telehealth stock with strong revenue growth, innovative offerings, and long-term potential. Click here ...

Hims & Hers Health showed a sharper-than-expected revenue hiccup in Q2, sending the stock down. Click here to find out why ...

At $13.6 billion in market capitalization, Hims & Hers stock costs a pricey 70 times trailing earnings. It's even more ...

The telehealth-consultation platform posted an increase in profit and revenue for the second quarter on growth in subscribers ...

Hims & Hers stock (NASDAQ: HIMS) fell approximately 13% in after-hours trading following Q2 results that demonstrated strong ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Shares of Hims & Hers Inc. fell after hours on Monday after the wellness and telehealth platform’s third-quarter forecast ...

Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

Hims & Hers Health (HIMS) stock falls after reporting lower Q2 revenues. Analysts caution about near-term challenges, ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...